Looking for ideas before Christmas? These 2 ASX shares stand out to me

Two ASX shares at opposite ends of the market are catching my attention as the year draws to a close.

| More on:
ecommerce asx shares represented by santa doing online shopping on laptop

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Despite previous challenges, CSL offers potential growth and stability with improving plasma collections and strong demand for its healthcare products.
  • Known for its notable dividend yield of approximately 11%, Accent presents an attractive option for income-focused investors keen on retail sector resilience.
  • Both CSL and Accent are compelling options for those seeking either long-term growth or immediate income as the year draws to a close.

As Christmas approaches, plenty of investors start thinking about where to put fresh money to work before the new year. I am no different. With markets still a bit choppy and sentiment mixed across sectors, I have been focusing on quality businesses where the risk-reward balance looks attractive heading into 2026.

Two ASX shares are standing out to me right now, despite sitting at opposite ends of the market. For different reasons, both are worth a closer look.

CSL Ltd (ASX: CSL)

The CSL share price has had a tough run over the past year and is trading around $175, well below the levels investors had become used to. Softer profit guidance, higher costs, and a slower-than-expected recovery in plasma collections weighed on sentiment, and the market did not take kindly to that.

That being said, the long-term story has not broken. Plasma collections have been improving, Seqirus continues to perform solidly, and CSL Vifor is starting to settle after a challenging integration period. Cost discipline is also coming into focus, which is usually the first step toward margin recovery.

Several brokers continue to describe CSL as oversold, with price targets well above current levels. For a global healthcare leader with a long track record of growth, a strong balance sheet, and solid demand for immunoglobulin and vaccines, the current share price is starting to look far more appealing than it did a year ago.

If CSL can show steadier execution across FY26, the share price could start to find support.

Accent Group Ltd (ASX: AX1)

At the other end of the spectrum sits Accent, with its share price trading around 90 cents. The footwear retailer owns well-known brands such as Platypus, Hype DC and The Athlete's Foot, and it has built a strong omnichannel business across Australia and New Zealand.

What really stands out here is income. Accent paid 10 cents per share in fully franked dividends over the past year, which puts the trailing yield at roughly 11% at current prices. That is a big number for an ASX 200 stock.

While retail always carries some risk, Accent has performed better than many of its peers, with resilient margins and solid digital sales. Management continues to invest in store rollouts and owned brands, which support earnings over time.

For income-focused investors who are comfortable with some volatility, Accent offers a level of yield that is hard to ignore.

Foolish Takeaway

CSL and Accent Group are very different businesses, but both stand out to me as we head into Christmas. CSL offers quality and long-term growth at a much lower price than usual, while Accent provides immediate income at an attractive yield.

For investors looking to add ideas before the year ends, these two ASX shares are well worth having on the watchlist.

Motley Fool contributor Aaron Teboneras has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended Accent Group and CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman screams and holds her hands up in frustration.
Healthcare Shares

Pro Medicus shares crash 22% despite record results. Is this a rare buying opportunity?

Pro Medicus shares plunge despite strong earnings and record margins.

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Here's an ASX 200 share that I think could beat CSL in 2026

I think this ASX 200 stock has more potential.

Read more »

Happy healthcare workers in a labs
Healthcare Shares

Why Neuren shares are edging lower on Thursday

Neuren shares slip despite management announcing a new buyback program.

Read more »

Young doctor raising arms in air with hands in fists celebrating a new development
Healthcare Shares

Why this ASX healthcare share could double its value in 2026

Brokers are tipping a breakthrough year for the biotech company.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

3 reasons to target global healthcare in 2026 -expert

Should investors be buying healthcare shares this year?

Read more »

A bored woman looking at her computer, it's bad news.
Healthcare Shares

CSL shares crash 12% on half-year results and shock CEO exit

It goes from bad to worse for this struggling company.

Read more »

Close-up of a business man's hand stacking gold coins into piles on a desktop.
Dividend Investing

Here's everything you need to know about CSL's upcoming dividend

CSL has confirmed its next dividend after a sharp sell-off sent its shares to multi-year lows.

Read more »

Silhouette of CEO standing in conference room looking out at cityscape.
Healthcare Shares

CSL prepares for half-year results as CEO transition comes into focus

CSL prepares to report its half-year results as investors digest a surprise CEO transition.

Read more »